EQUITIES news

L&T rating: Buy with revised target price of Rs 1,826

While the revenue decline is deeper than our estimate, we reckon the 9–10% decline in guidance for FY21 implies a 2% CQGR for the remaining quarters, which is encouraging.

L&T Technology Services (LTTS) reported a dollar revenue drop of 12.5% q-o-q in Q1 FY21 versus our estimate of a 9.5% decline. EBIT margin dipped to 12.1%, much below our estimate of 13.3%. Revenue contraction is attributable to a sharp q-o-q decline of 22.8%/24.2% in the transportation/plant engineering (PE) business overwhelming the robust 9.2% q-o-q growth in medical devices. Management guided for a 9–10% dip in FY21 topline, along with a potential recovery in growth and margins from Q2 itself. This implies a 2% CQGR for the remaining quarters of FY21. While we remain bullish on the long-term prospects of the fast-growing ER&D and believe LTTS is in a pole position to benefit thereof, the current quarter miss leads to a marginal cut of 3.5/2.5% in FY21/22E EPS. Maintain buy with a revised TP of Rs 1,826 (versus Rs 1,872 earlier; 20x FY22E) at 20x FY22E EPS.

Covid-19 hits plant engineering and transportation hard: The 12.5% q-o-q drop in revenue, although steeper than our estimate, is not scary as the bulk of damage arose from transportation/PE (down ~22.8/24% q-o-q)— hit hard by the pandemic as factories remained largely closed with limited activity. While the revenue decline is deeper than our estimate, we reckon the 9–10% decline in guidance for FY21 implies a 2% CQGR for the remaining quarters, which is encouraging.

Related News

Rationale for margin miss: Capacity retention for future execution Ebitda margin eroded 260bps q-o-q to 15.9%, largely due to a 670bps q-o-q fall-off in gross margin that was somewhat offset by lower SG&A expenses. The plunge in gross margin is attributable to an almost 800bps q-o-q drop in utilisation, which management attributed to their decision to maintain capacity for future execution.

Outlook and valuation, weak numbers, improving outlook: Uncertainty continues to mar the outlook for ER&D revenue growth, now further undermined by the Covid-19 crisis. We believe unlike IT services wherein higher online activity has been a saviour of demand, ER&D business growth hinges on plant operations and transportation (aviation etc). While the numbers did miss our estimates and a marginal cut in inescapable, we believe bounce-back will be sharper than management guidance, although lockdowns in case of a second wave of the virus remains a key risk. Retain buy/SO with a revised TP of Rs 1,826 (earlier Rs 1872 20x FY22E).

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Source

Related Posts